Vanessa, a travel nurse from Memphis, Tennessee, had her life meticulously planned. She was building her career, saving for a home, and looking forward to a future she had worked hard to create. That all changed when she was diagnosed with stage 3 triple-negative breast cancer, the most aggressive subtype. The diagnosis forced her to put her life on hold and focus entirely on treatment.
Even as a nurse, Vanessa found herself in unfamiliar territory. 'I've taken care of patients my whole life,' she says. 'But I didn't really know what breast cancer truly entailed.' Treatment began quickly, and in the months that followed, she navigated the uncertainty and emotional toll of the disease. Then came the news every cancer patient dreads: the cancer had spread, and Vanessa was now facing metastatic triple-negative breast cancer.
Triple-negative breast cancer tends to grow and spread more quickly than many other types. For about half of women with metastatic triple-negative breast cancer, their first treatment might be their only opportunity to keep the cancer from growing, making it critical to choose the best option on day one. This subtype also occurs more often in younger women and appears at higher rates in Black and Hispanic women, making access to education a matter of survival for these communities.
Vanessa wanted to clearly understand her treatment options and what questions to ask her doctor. She learned that historically, metastatic triple-negative breast cancer treatment options were limited to chemotherapy-based therapy. However, her doctor suggested a clinical trial for a newer class of medicine called antibody-drug conjugates (ADCs). Unlike traditional chemotherapy, ADCs are designed to find specific markers and deliver medicines more directly to cancer cells. Until recently, ADCs were used later in treatment, but now patients may receive them as a first treatment after diagnosis.
Innovations like ADCs have already made a difference for many patients by helping to keep cancer from growing. For Vanessa, that means being able to plan ahead, knowing her good days and bad days—whether that's the next girls' trip or time with family. However, not all ADCs are the same; safety and efficacy can vary. While not every patient will be eligible, understanding when they may be considered and how treatment can impact daily life can help patients feel more informed when discussing options with their care team.
Dr. Gregory Vidal, Vanessa's medical oncologist and Director of Clinical Research at West Cancer Center, emphasizes considering patients' goals, wishes, and needs when selecting treatment. 'All patients are different and may qualify for different ADCs,' he says. He encourages patients to have open conversations with their care team and ask questions about treatment goals.
Every person's experience is different, but many people with metastatic breast cancer remain on treatment for life, aiming to manage the disease and slow progression while maintaining quality of life. Vanessa leaned on her close friends and family to keep 'faith over fear' by focusing on positives and planning outings around her treatments. She encourages others to stay positive, ask questions, and advocate for themselves. 'You definitely have a fight in front of you, but you can get through this,' she says. 'You have to do your research and get answers.'
To see how Vanessa and others navigate ADC treatment for metastatic triple-negative breast cancer, visit Expose-MBC.com/ADC.
